Connection

GABRIEL LOPEZ to Breast Neoplasms

This is a "connection" page, showing publications GABRIEL LOPEZ has written about Breast Neoplasms.
Connection Strength

0.489
  1. FOXM1 mediates Dox resistance in breast cancer by enhancing DNA repair. Carcinogenesis. 2012 Oct; 33(10):1843-53.
    View in: PubMed
    Score: 0.074
  2. Her2/neu induces all-trans retinoic acid (ATRA) resistance in breast cancer cells. Oncogene. 2002 Aug 08; 21(34):5224-32.
    View in: PubMed
    Score: 0.037
  3. Bcl-2-related antisense therapy. Semin Oncol. 2002 Jun; 29(3 Suppl 11):71-6.
    View in: PubMed
    Score: 0.037
  4. Modulation of Akt activity by doxorubicin in breast cancer cells. J Chemother. 2001 Jun; 13(3):334-6.
    View in: PubMed
    Score: 0.035
  5. Grb2 downregulation leads to Akt inactivation in heregulin-stimulated and ErbB2-overexpressing breast cancer cells. Oncogene. 2000 Dec 14; 19(54):6271-6.
    View in: PubMed
    Score: 0.033
  6. Growth inhibition of breast cancer cells by Grb2 downregulation is correlated with inactivation of mitogen-activated protein kinase in EGFR, but not in ErbB2, cells. Oncogene. 1999 Feb 11; 18(6):1325-32.
    View in: PubMed
    Score: 0.029
  7. A Phase I multicenter study of E1A gene therapy for patients with metastatic breast cancer and epithelial ovarian cancer that overexpresses HER-2/neu or epithelial ovarian cancer. Hum Gene Ther. 1998 Aug 10; 9(12):1775-98.
    View in: PubMed
    Score: 0.028
  8. Copy number gain of hsa-miR-569 at 3q26.2 leads to loss of TP53INP1 and aggressiveness of epithelial cancers. Cancer Cell. 2014 Dec 08; 26(6):863-879.
    View in: PubMed
    Score: 0.022
  9. Targeted silencing of elongation factor 2 kinase suppresses growth and sensitizes tumors to doxorubicin in an orthotopic model of breast cancer. PLoS One. 2012; 7(7):e41171.
    View in: PubMed
    Score: 0.019
  10. Targeting the PELP1-KDM1 axis as a potential therapeutic strategy for breast cancer. Breast Cancer Res. 2012 Jul 19; 14(4):R108.
    View in: PubMed
    Score: 0.019
  11. Clinical and biological relevance of enhancer of zeste homolog 2 in triple-negative breast cancer. Hum Pathol. 2012 Oct; 43(10):1638-44.
    View in: PubMed
    Score: 0.018
  12. Chitosan hydrogel for localized gene silencing. Cancer Biol Ther. 2011 May 01; 11(9):839-45.
    View in: PubMed
    Score: 0.017
  13. Targeting p70S6K prevented lung metastasis in a breast cancer xenograft model. Mol Cancer Ther. 2010 May; 9(5):1180-7.
    View in: PubMed
    Score: 0.016
  14. Silencing of Bcl-2 expression by small interfering RNA induces autophagic cell death in MCF-7 breast cancer cells. Autophagy. 2008 Jul; 4(5):669-79.
    View in: PubMed
    Score: 0.014
  15. Silk fibroin mediated delivery of liposomal emodin to breast cancer cells. Int J Pharm. 2007 Aug 16; 341(1-2):221-9.
    View in: PubMed
    Score: 0.013
  16. Mutant Bik expression mediated by the enhanced minimal topoisomerase IIalpha promoter selectively suppressed breast tumors in an animal model. Cancer Gene Ther. 2006 Jul; 13(7):706-19.
    View in: PubMed
    Score: 0.012
  17. Liposomal antisense oligonucleotides for cancer therapy. Methods Enzymol. 2004; 387:241-53.
    View in: PubMed
    Score: 0.010
  18. Downregulation of Wilms' tumor 1 protein inhibits breast cancer proliferation. Biochem Biophys Res Commun. 2002 Jul 26; 295(4):784-90.
    View in: PubMed
    Score: 0.009
  19. The potential of drug-carrying immunoliposomes as anticancer agents. Commentary re: J. W. Park et al., Anti-HER2 immunoliposomes: enhanced efficacy due to targeted delivery. Clin. Cancer Res., 8: 1172-1181, 2002. Clin Cancer Res. 2002 Apr; 8(4):955-6.
    View in: PubMed
    Score: 0.009
  20. Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial. J Clin Oncol. 2001 Jul 15; 19(14):3422-33.
    View in: PubMed
    Score: 0.009
  21. Phase I trial of intratumoral liposome E1A gene therapy in patients with recurrent breast and head and neck cancer. Clin Cancer Res. 2001 May; 7(5):1237-45.
    View in: PubMed
    Score: 0.009
  22. Serum predominantly activates MAPK and akt kinases in EGFR- and ErbB2-over-expressing cells, respectively. Int J Cancer. 2000 Apr 15; 86(2):295-7.
    View in: PubMed
    Score: 0.008
  23. Tumour angiogenesis regulation by the miR-200 family. Nat Commun. 2013; 4:2427.
    View in: PubMed
    Score: 0.005
  24. Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med. 2008 Dec 18; 359(25):2641-50.
    View in: PubMed
    Score: 0.004
  25. The activation of human monocytes by liposome-encapsulated muramyl dipeptide analogues. J Immunol. 1983 Apr; 130(4):1500-2.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.